DURECT Corporation DRRX

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
—
Insufficient data

Ranked against 90 peers in Drug Manufacturers - Specialty & Generic

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where DRRX ranks in Drug Manufacturers - Specialty & Generic

DURECT Corporation ranks #87 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 96%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

# Company Moat score Rating
83 Shuttle Pharmaceuticals Holding SHPH 6/100 Weak
84 Bright Green Corporation BGXX 5/100 Weak
85 CAN B CORP. CANB 0/100 Weak
86 Cyclo Therapeutics, Inc. CYTH 0/100 Weak
87 DURECT Corporation DRRX 0/100 Weak
88 Evoke Pharma, Inc. EVOK 0/100 Weak
89 Intra-Cellular Therapies Inc. ITCI 0/100 Weak
90 OptiNose, Inc. OPTN 0/100 Weak
91 Procaps Group, S.A. PROC 0/100 Weak

See every Pharma / Mature Biotech company ranked by moat score →

How DRRX scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Not measurable · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Not measurable · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding DRRX's moat

What is DURECT Corporation's moat score?

DURECT Corporation (DRRX) scores 0 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #87 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 96%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic.

How does DURECT Corporation compare with other Drug Manufacturers - Specialty & Generic companies?

DURECT Corporation ranks #87 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Cyclo Therapeutics, Inc. (CYTH) at 0 just above it and Evoke Pharma, Inc. (EVOK) at 0 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is DURECT Corporation scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for DURECT Corporation?

The Corporate Default template measures 6 defenses, and DRRX scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (not measurable), Resilience (not measurable), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000